Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting ...

The FDA launched a new Priority Review program, as uncertainty persists for the existing programme for paediatric disorders.

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing therapies for rare diseases, finds itself at a critical juncture as it navigates regulatory challenges and ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...

Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...